T lymphocyte activation through the C28 pathway is insensitive to inhibition by the immunosuppressive drug FK-506

J E Kay; C R Benzie

doi:10.1016/0165-2478(89)90129-6

T lymphocyte activation through the C28 pathway is insensitive to inhibition by the immunosuppressive drug FK-506

Immunol Lett. 1989 Dec;23(2):155-9. doi: 10.1016/0165-2478(89)90129-6.

Authors

J E Kay¹, C R Benzie

Affiliation

¹ Biochemistry Laboratory, School of Biological Sciences, University of Sussex, Brighton, U.K.

PMID: 2483716
DOI: 10.1016/0165-2478(89)90129-6

Abstract

Nanomolar concentrations of the novel immunosuppressive drug FK-506 inhibit the proliferation of human T lymphocytes in vitro induced by mitogenic lectins or by monoclonal antibodies directed against the CD3 or CD2 surface antigens. However, the alternative pathway of T lymphocyte proliferation induced by monoclonal antibodies specific for CD28 together with phorbol esters is unaffected by FK-506.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Anti-Bacterial Agents / pharmacology*
Antibodies, Monoclonal / pharmacology
Antigens, Differentiation, T-Lymphocyte*
CD2 Antigens
CD28 Antigens
CD3 Complex
Humans
Immunosuppressive Agents / pharmacology*
In Vitro Techniques
Lymphocyte Activation / drug effects*
Mitogens / pharmacology
Receptors, Antigen, T-Cell
Receptors, Immunologic
T-Lymphocytes / drug effects*
T-Lymphocytes / immunology
Tacrolimus

Substances

Anti-Bacterial Agents
Antibodies, Monoclonal
Antigens, Differentiation, T-Lymphocyte
CD2 Antigens
CD28 Antigens
CD3 Complex
Immunosuppressive Agents
Mitogens
Receptors, Antigen, T-Cell
Receptors, Immunologic
Tacrolimus